It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Emergency crews responded to N Hearne Avenue between Aero Drive and Shreveport Blanchard Highway. Officials with the Shreveport Police Department say a fisherman called 911 saying they saw a body out ...

Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc ...

(Reuters) -Novo Nordisk has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday. Bloomberg News first reported on ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

LONDON/COPENHAGEN, Oct 15 (Reuters) - Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a ...

C2 Racing Stable, Gary Barber, and La Milagrosa Stable's White Abarrio breezed a half-mile in company Oct. 9 at Gulfstream Park in preparation for a planned start in the $1 million Breeders' Cup Dirt ...

Dom Toretto may live his life a quarter mile at a time, but you know who doesn't? Drivers in the NHRA's Top Fuel and Funny Car classes. Organized drag racing has been around since at least the late ...

Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.